AIHTA - Publications - Search - Enzalutamide (Xtandi®) for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT)

Grössmann, N. (2021): Enzalutamide (Xtandi®) for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT). Oncology Fact Sheet Nr. 46.

[thumbnail of Oncology Fact Sheet Nr.46.pdf]
Preview
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
439kB

Item Type:Oncology Fact Sheet
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WJ Urogenital system > WJ 700-875 Male genitalia
Language:English
Series Name:Oncology Fact Sheet Nr. 46
Deposited on:16 Apr 2021 13:17
Last Modified:16 Apr 2021 13:17

Repository Staff Only: item control page